
A vaginal estradiol hormone tablet and over-the-counter vaginal moisturizer were not beneficial than a placebo vaginal tablet and gel in reducing postmenopausal vulvovaginal symptoms in women.
Many postmenopausal women have bothersome vulvovaginal symptoms, including vaginal dryness, itching and pain with sex.
‘Understanding of postmenopausal vulvovaginal symptoms is more needed to improve treatment options.’
Tweet it Now
Treatment recommendations for these symptoms focus mostly on vaginal products but issues with those treatments include messiness, expense, safety concerns and a lack of symptom relief.
This study evaluated the efficacy of vaginal estradiol tablets and a vaginal moisturizer in women with moderate to severe vulvovaginal symptoms.
About 302 postmenopausal women with moderate to severe symptoms in a 12-week randomized clinical trial.
The main outcome was a decrease in the reported severity of symptoms. This was a randomized clinical trial (RCT). RCTs allow for the strongest inferences to be made about the true effect of an intervention.
However, not all RCT results can be replicated in real-world settings because patient characteristics or other variables may differ from those studied in the RCT.
The authors of the study were Caroline M. Mitchell, M.D., of Massachusetts General Hospital, Boston, and coauthors.
Vaginal estradiol tablets plus placebo gel and a vaginal moisturizer plus a placebo tablet were not better than dual placebo tablets and gel at reducing symptom severity or improving sexual function.
The generalizability of study results is limited by the relatively homogeneous study population.
A better understanding of the underlying mechanism of postmenopausal vulvovaginal symptoms is needed to guide efforts to improve treatment options.
Source: Eurekalert
About 302 postmenopausal women with moderate to severe symptoms in a 12-week randomized clinical trial.
The main outcome was a decrease in the reported severity of symptoms. This was a randomized clinical trial (RCT). RCTs allow for the strongest inferences to be made about the true effect of an intervention.
However, not all RCT results can be replicated in real-world settings because patient characteristics or other variables may differ from those studied in the RCT.
The authors of the study were Caroline M. Mitchell, M.D., of Massachusetts General Hospital, Boston, and coauthors.
Vaginal estradiol tablets plus placebo gel and a vaginal moisturizer plus a placebo tablet were not better than dual placebo tablets and gel at reducing symptom severity or improving sexual function.
The generalizability of study results is limited by the relatively homogeneous study population.
A better understanding of the underlying mechanism of postmenopausal vulvovaginal symptoms is needed to guide efforts to improve treatment options.
Source: Eurekalert
Recommended Reading
Latest Women Health News

Women over 45 years old taking estrogen pills have a higher likelihood of developing high blood pressure compared to those using transdermal or vaginal formulations.

The new study assessed the beneficial effects of nitroglycerin patches in treating hot flashes in postmenopausal women.

A new study investigated the rate of neural tube defects in predominantly Hispanic-populated women before and after the voluntary fortification of corn masa flour with folic acid.

Experts suggest that getting regular mammograms at the age of 40 can help women prevent breast cancer.

The commonly used Fracture Risk Assessment Tool (FRAX) is not useful for shared clinical decision-making regarding osteoporosis screening in younger postmenopausal women.